RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 129 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 1.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,559,469 | -38.2% | 465,290 | -39.6% | 0.00% | -100.0% |
Q2 2023 | $5,757,562 | +32.7% | 770,758 | +18.4% | 0.00% | 0.0% |
Q1 2023 | $4,340,269 | -28.9% | 650,715 | -17.8% | 0.00% | 0.0% |
Q4 2022 | $6,102,851 | +7.8% | 791,550 | +48.7% | 0.00% | 0.0% |
Q3 2022 | $5,663,000 | +98.0% | 532,370 | +51.5% | 0.00% | 0.0% |
Q2 2022 | $2,860,000 | -57.1% | 351,372 | -62.3% | 0.00% | 0.0% |
Q1 2022 | $6,666,000 | +79.3% | 931,070 | +329.1% | 0.00% | 0.0% |
Q4 2021 | $3,718,000 | +327.4% | 217,007 | +474.1% | 0.00% | – |
Q3 2021 | $870,000 | +278.3% | 37,800 | +500.0% | 0.00% | – |
Q2 2021 | $230,000 | – | 6,300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Obvious Management Services, L.L.C. | 3,985,087 | $42,401,000 | 100.00% |
Two Sigma Ventures, LP | 903,400 | $9,612,000 | 100.00% |
DCVC Opportunity Fund II GP, LLC | 3,951,141 | $42,040,000 | 54.37% |
Data Collective IV GP, LLC | 5,941,120 | $63,214,000 | 49.97% |
MIC Capital Management UK LLP | 8,451,758 | $89,927,000 | 16.21% |
MV Management XI, L.L.C. | 1,971,908 | $20,981,000 | 15.20% |
ArchPoint Investors | 1,116,126 | $11,876,000 | 4.85% |
HARVARD MANAGEMENT CO INC | 1,509,254 | $16,058,000 | 2.00% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,251,971 | $23,961,000 | 1.00% |
Duquesne Family Office | 1,385,950 | $14,747,000 | 0.84% |